COO - Educational Analysis * US Equities
Educational Analysis * US Equities

COO

Earnings behavior, post-earnings drift, and the gap between consensus and the market's real expectation - the educational primer before you look at the institutional verdict.

Educational content only - not investment advice. Nothing on this page is a recommendation to buy or sell any security. Historical patterns do not predict future outcomes. Consult a licensed financial advisor before making any trading decision.
Published byGamma QC editorial
TickerCOO
CategoryEducational primer
Last reviewedNovember 16, 2026
You're viewing an older edition of this page.Read the latest edition →

Business profile & competitive position

The Cooper Companies, Inc. (COO) operates in the Healthcare sector, specifically the Medical - Instruments & Supplies industry, as a global medical device company headquartered in San Ramon, California. Its operations are organized into two segments. CooperVision develops, manufactures, and markets a broad range of single-use, two-week, and monthly contact lenses, including silicone hydrogel lenses, myopia management products such as MiSight 1 day, orthokeratology lenses, and scleral lenses. CooperSurgical offers more than 600 products and services focused on fertility and women's health, spanning gynecology, obstetrics, contraception, labor and delivery, cord blood and tissue storage, IVF support, donor gametes, cryopreservation, and genomic services.

The company's financial returns suggest meaningful scale without outsized capital efficiency. Net margin is 13.5% and ROE stands at 6.9%. A sub-7% ROE is relatively modest for a healthcare device franchise and implies that, while Cooper's portfolio covers specialized niches like myopia management and fertility solutions, its competitive moat is better described as durable rather than exceptionally wide. The operating model requires ongoing manufacturing, distribution, R&D, and regulatory investment. Approximately 500 employees work in research and development across both segments.

Cooper's products are sold in over 130 countries and positively impact more than fifty million lives each year, according to its most recent 10-K. MiSight 1 day holds a notable regulatory position: it is the only contact lens approved by the FDA, Chinese NMPA, and Japanese MHLW to slow the progression of, and correct, myopia in age-appropriate children. That regulatory differentiation is a tangible, if narrow, competitive advantage within CooperVision's growing myopia management focus.

Financial posture

At a price of $62.036, Cooper carries a market capitalization of $11.8 billion and trades at a P/E ratio of 21.2. The valuation implies the market expects steady, rather than explosive, earnings growth from a relatively mature medical device provider. Net margin of 13.5% is healthy and reflects the company's ability to price its specialty lenses, fertility, and women's health offerings above manufacturing cost, but it is not at the top tier of margin-rich medical technology companies.

Return on equity of 6.9% is the figure that stands out most. For a capital-intensive healthcare device company, that ROE suggests the balance sheet retains meaningful equity capital relative to the earnings it generates. The stock has a beta of 0.82, indicating lower volatility than the broader market, which is consistent with a defensive healthcare name tied to recurring purchase patterns such as contact lens replacements. The current RSI of 54.1 and 50-day EMA of $61.34 place the stock near technical equilibrium.

Strategic priorities & outlook

Cooper's most recent 10-K filing outlines four near-term operational priorities that map directly to its two business units. CooperVision is focused on greater worldwide market penetration of recently introduced products and on expanding its presence in both existing and emerging markets. It is also increasing investment in distribution and packaging capabilities to support business growth and quality service levels. Separately, CooperVision is investing to develop the myopia management market by educating eye care practitioners, patients, and their families.

At CooperSurgical, the strategic emphasis is on continuing to invest in the business, including through strategic transactions, in order to expand its integrated solutions model within fertility and women's health. The combination of organic market development and bolt-on M&A suggests Cooper is trying to deepen recurring revenue streams and build out vertically adjacent services, such as IVF support and cryopreservation, alongside its traditional medical device product lines.

Macro & geopolitical exposure

As a Medical - Instruments & Supplies company, Cooper operates in an industry defined by regulatory, trade, currency, and supply-chain sensitivities. Contact lenses and fertility devices are regulated medical products, so approvals and compliance with bodies such as the FDA, China's NMPA, and Japan's MHLW are central to market access. Shifts in regulatory pathways, quality standards, or post-market surveillance requirements can affect product launches and margins.

The global distribution footprint—sales in over 130 countries—also exposes the company to foreign exchange translation and transactional risk. Medical device firms with significant overseas revenue routinely see reported results buffeted by dollar strength or weakness. On the trade side, contact lenses and related packaging materials can be subject to tariffs, import quotas, or local content rules, particularly in regions that prioritize domestic manufacturing of healthcare products. Supply-chain exposure includes the sourcing of silicone hydrogel polymers, packaging components, and specialized equipment used in fertility clinics. Healthcare reimbursement trends and demographic shifts, such as population aging and changing birth rates, also influence demand for women's health and fertility services over multiyear cycles.

Recent developments

The most recent news flow for Cooper, dated November 2026, has centered entirely on investor-counsel advertisements rather than operational or financial announcements. On November 15, 2026, Globenewswire carried a Rosen Law Firm notice encouraging investors who suffered losses to contact the firm regarding their rights. A similar notice appeared on Globenewswire on November 12, 2026. On November 13, 2026, Newsfilecorp published a Rosen Law Firm release encouraging investors to inquire about a securities class action investigation, and on November 10, 2026, PRNewswire carried an equivalent notice.

These releases follow a standard plaintiff-firm marketing pattern around securities litigation inquiries. They do not, by themselves, establish wrongdoing or predict a material financial outcome, but they can create headline risk in the weeks before an earnings report. The clustering of these notices around the November 10-15 window comes just ahead of Cooper's next scheduled earnings release on December 3, 2026.

Earnings behavior & post-earnings drift

Cooper's earnings record over the trailing eight quarters is technically flawless: the company beat consensus earnings estimates in all eight periods, for a 100% beat rate. The average earnings surprise across those eight reports was 4.2%. Despite this consistent outperformance, the average 5-day price move following earnings was negative 2.34%, classified as a "down" post-earnings drift.

This divergence between earnings beats and post-report price action is the central pattern to understand. The last four reported quarters illustrate the dynamic clearly. On September 9, 2026, Cooper reported EPS of $1.15 against an estimate of $1.12, a 2.7% beat, yet the stock fell 14.67% the next day and 13.97% over the following five trading days. On March 5, 2026, the company delivered $1.10 versus $1.03, a 6.8% beat, but the stock dropped 4.55% the next day and 10.82% over the next five days. These negative reactions occurred alongside two positive examples: the June 4, 2026 report, where a 10% beat on $1.21 versus $1.10 produced an 8.58% next-day gain and an 8.85% five-day gain, and the December 4, 2025 report, where a 3.6% beat on $1.15 versus $1.11 drove a 5.67% next-day pop and a 6.59% five-day advance.

The takeaway is that beating estimates has not reliably translated into follow-through price appreciation for COO. The unofficial consensus may be embedded in full-year guidance, segment commentary, or margin trajectory rather than in the headline EPS number alone. With the next scheduled report on December 3, 2026, after the market close, the consensus EPS estimate is $1.07. A beat on that figure is historically likely, but the historical record shows that the price reaction afterward has been directionally mixed and, on balance, negative over the following week.

Frequently Asked Questions

What does The Cooper Companies actually do?

Cooper is a global medical device company operating through CooperVision, which makes contact lenses and myopia management products, and CooperSurgical, which provides fertility and women's health devices and services including IVF support, cryopreservation, and genomic services.

Why does COO stock sometimes fall after beating earnings estimates?

Even though Cooper has beaten EPS estimates in 8 of the last 8 quarters, the average 5-day post-earnings move has been -2.34%. The market's real expectation appears to reflect guidance, margin trends, or segment commentary rather than the headline beat alone, which can produce sharp sell-offs on otherwise positive EPS prints.

What are Cooper's main strategic priorities?

According to its most recent 10-K, CooperVision aims to expand global penetration of new products, invest in distribution and packaging, and develop the myopia management market through education. CooperSurgical is focused on growing through strategic transactions to build an integrated fertility and women's health platform.

For a more complete picture of how institutional analysts view Cooper's risk/reward heading into the December 3, 2026 earnings report, consult the full institutional verdict and consensus breakdown on the platform.

Real Data - Gamma QC Earnings IntelligenceAs of Nov 16, 2026
The Cooper Companies, Inc. · Healthcare / Medical - Instruments & Supplies
$11.8BMarket cap
21.2P/E
13.5%Net margin
6.9%ROE
100%Beat rate, last 8Q
4.2%Avg EPS surprise
-2.34%Avg 5-day move after earnings
2026-12-03Next earnings
ReportedActualEstimateSurprise1D Move5D Move
2026-09-09$1.15$1.12+2.7%-14.67%-13.97%
2026-06-04$1.21$1.1+10%+8.58%+8.85%
2026-03-05$1.1$1.03+6.8%-4.55%-10.82%
2025-12-04$1.15$1.11+3.6%+5.67%+6.59%
2025-08-27$1.1$1.07+2.8%--
2025-05-29$0.96$0.928+3.4%--

Previous COO editions

Beyond the primer

Get the institutional verdict on COO

Seven-seat 21-ERT council. Pre-print forecast signed before the earnings release. Post-print grade, published in public. Every verdict sealed with a cryptographic receipt.

Read the COO verdict at Gamma QC
$49 Pro / $249 RIA * gammaqc.com

Verify authenticity

Every Gamma QC verdict is signed with a cryptographic receipt at issuance. Independently verify any published verdict at attest.gammaqc.com. This educational primer is content-only and not itself signed; the institutional verdict at the link above is.